New Therapies for Chronic Spontaneous Urticaria Expand Options Beyond Anti-IgE Care

— Dermatologists can now take more control of treating CSU patients, says Gil Yosipovitch by Gregory Laub, Senior Director, Video, MedPage Today May 1, 2026 • 1 min read Discussions at the American Academy of Dermatology annual meeting highlighted a rapidly evolving treatment landscape for chronic spontaneous urticaria (CSU), with new targeted therapies expanding options beyond traditional antihistamines and anti-immunoglobulin E (IgE) approaches. In this exclusive MedPage Today video, Gil Yosipovitch, MD, of the University of Miami Miller School of Medicine, reflects on the past year of approvals and what they mean for dermatologists taking a more central role in managing CSU. Following is a transcript of his remarks: So big, major advances have occurred in the last year with approval of two drugs that target the neuroimmune system and mast cells. One that we are all familiar [with] as dermatologists because it's been in the market for the last 10 years is dupilumab (Dupixent). It is a biologic injectable targeting the IL [interleukin]-4 receptor and this cascade affects the neuroimmune aspect of chronic urticaria. And second is a drug that targets the mast cell that is an oral medication, remibrutinib (Rhapsido), which is a Bruton's tyrosine kinase [inhibitor]. And